Specialty pharmacist integration into an outpatient neurology clinic improves pimavanserin access

Specialty pharmacist integration into an outpatient neurology clinic improves pimavanserin access

Introduction: Access to pimavanserin, the only Parkinson disease–related psychosis treatment approved by the FDA, is restricted by insurance requirements, a limited distribution network, and high costs. Following initiation, patients require monitoring for safety and effectiveness. The primary objec...

Full description

Bibliographic Details
Main Authors: Sabrina Livezey, PharmD, CSP, Nisha B. Shah, PharmD, Robert McCormick, PharmD, Josh DeClercq, MS, Leena Choi, PhD, Autumn D. Zuckerman, PharmD, BCPS, AAHIVP, CSP
Format: Article
Language:English
Published: American Association of Psychiatric Pharmacists 2021-05-01
Series:Mental Health Clinician
Subjects:
pimavanserin
specialty pharmacy
medication access
limited distribution
Online Access:https://theijpt.org/doi/pdf/10.9740/mhc.2021.05.187

Internet

https://theijpt.org/doi/pdf/10.9740/mhc.2021.05.187

Similar Items